{"id":16399,"date":"2022-12-08T15:33:16","date_gmt":"2022-12-08T14:33:16","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16399"},"modified":"2024-12-11T18:40:02","modified_gmt":"2024-12-11T17:40:02","slug":"lal-b-suivi-a-long-terme-des-patients-traites-par-tisagenlecleucel","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/lal-b-suivi-a-long-terme-des-patients-traites-par-tisagenlecleucel\/","title":{"rendered":"LAL-B : suivi \u00e0 long terme des patients trait\u00e9s par tisagenlecleucel"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. : HematoStat.net ; 3 (4) : R68<\/p>\n<p><i><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36399695\/\">Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 18 nov 2022;JCO.22.00642.<\/a><\/i><\/p>\n<h3>R\u00e9sum\u00e9 de l&#8217;article<\/h3>\n<p>Le tisagenlecleucel (tisa-cel) est un CAR T anti-CD19 destin\u00e9 au traitement des leuc\u00e9mies lymphoblastiques B (LAL-B) en rechute ou r\u00e9fractaire. Les auteurs pr\u00e9sentent les r\u00e9sultats \u00e0 long terme de l\u2019essai ELIANA. \u00c0 3 ans et pour les patients r\u00e9infus\u00e9s, la survie sans progression \u00e9tait estim\u00e9e \u00e0 47,8 % (IC95 %, 34,4-60) et la survie \u00e0 63 % (IC95 %, 51-73) Apr\u00e8s 1 an, la proportion des patients pr\u00e9sentant un effet secondaire de grade 3-4 baissait et \u00e9tait de 29 %.<\/p>\n<h3>Dans nos pratiques<\/h3>\n<p>Le tisa-cel, seul CAR T ayant l\u2019AMM dans la LAL-B, a r\u00e9volutionn\u00e9 la prise en charge des malades avec LAL-B r\u00e9fractaire ou en rechute. Les tr\u00e8s bons r\u00e9sultats initiaux se confirment avec environ 1 patients sur 2 qui demeurent en r\u00e9ponse \u00e0 3 ans. Plus r\u00e9cemment, l\u2019analyse finale de l\u2019\u00e9tude a \u00e9t\u00e9 d\u00e9voil\u00e9e (EHA 2022) et le taux de survie \u00e0 5 ans est \u00e9valu\u00e9e \u00e0 55% (IC95 %, 43-66).<\/p>\n<h3>Regard du biostatisticien<\/h3>\n<p>Cette publication d\u00e9crivant les r\u00e9sultats \u00e0 plus long terme de l\u2019essai ELIANA (phase 2) ne d\u00e9roge aux analyses standards relatives \u00e0 ce type d\u2019\u00e9tude. Seul b\u00e9mol : la courbe de survie en fonction de l\u2019obtention du d\u00e9lai de r\u00e9tablissement des cellules B est biais\u00e9e par le caract\u00e8re temps-d\u00e9pendant de cette variable, elle doit \u00eatre prise avec recul.<span class=\"Apple-converted-space\"> <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":15574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[58,363],"ppma_author":[456],"class_list":["post-16399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","tag-car-t","tag-tisagenlecleucel","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16399"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16399\/revisions"}],"predecessor-version":[{"id":18242,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16399\/revisions\/18242"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16399"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}